News

Date
Title
Sort By:
08/27/24
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
08/08/24
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/23/24
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
05/08/24
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/30/24
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
04/09/24
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
03/28/24
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
01/30/24
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
01/29/24
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
01/05/24
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy